(Q33331027)

25 July 2017

title

Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma (English)

1 reference

25 July 2017

Haq R

1

1 reference

25 July 2017

Sawka CA

series ordinal

2

1 reference

25 July 2017

Franssen E

series ordinal

3

1 reference

25 July 2017

Berinstein NL

series ordinal

4

1 reference

25 July 2017

publication date

1 November 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

35

1 reference

25 July 2017

issue

5-6

1 reference

25 July 2017

page(s)

527-536

1 reference

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

Treatment of resistant non-Hodgkin’s lymphomas with cisplatin, etoposide, and bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

Mini-beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428199909169617

10.1080/10428199909169617

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference